To date, in 2010 NovAliX recorded the following:

Drug Discovery deal:
NovAliX initiated a drug discovery deal with a pharmaceutical company based on its target validation results for an orphan GPCR using its natural product-based approach.

In 2009 NovaliX had the following results:

Technology deal:
NovAliX has signed a technology deal with a top ten pharma based on its native nano ESI-MS screening technology for screening and characterization of small molecule and fragment libraries.

Drug Discovery deal:
NovaliX medicinal chemistry and structural biology group had one client kinase based program moving to development.

Process development:
NovAliX chemistry team had two processes taken to pilot plan at pharmaceutical partners’ facility.